Constellation 0209-01 A Phase 1/2 Study Of Cpi-0209 Monotherapy And In Combination With Other Therapy In Patients With Advanced Tumors
Posted Date: Jul 13, 2021
- Investigator: Shuchi Gulati
- Specialties: Cancer, Oncology
- Type of Study: Drug
The primary objective of this study is to study CPI-0209 in patients with advanced tumors alone and in combination with other therapies. CPI-0209 is a small molecule inhibitor of EZH2. Efficacy will be measured by Frequency of Dose-limiting toxicities.
Recovered To Baseline Or Grade = 1 Severity From Toxicity Related To Prior Treatments, Unless Aes Are Clinically Non-Significant And/Or Stable On Supportive Therapy. Ecog 0-1. Adequate Bone Marrow Function. Adequate Renal Function. Adequate Liver Function. No Previous Solid Organ Or Hematopoietic Cell Transplant. No Known Brain Metatstases. No Prior Ezh2 Inhibitor. No Concomitant Medication(S) Or Food Or Beverage That Are Moderate Or Strong Cyp3a Inducers Or Inhibitors Within 2 Weeks Prior To The First Dose Of Study Drug. No Clinically Significant Cardiovascular Disease. No Major Surgery Within 4 Weeks. No Gi Disorders Affecting Absorption. No Suspected Pneumonitis Or Interstitial Lung Disease. No Known Hiv Or Active Hepatitis. No Chronic Liver Disease.
For More Information:
Uc Cancer Center